Insider · CIK 0001784487
John Lunger
Files at ADAPY (Adaptimmune Therapeutics PLC). First filing Jan 15, 2025, latest Jan 17, 2025.
John Lunger files SEC Form 4 as officer at ADAPY (Adaptimmune Therapeutics PLC). Since Jan 15, 2025, John Lunger has reported 0 open-market buys worth $0 and 2 open-market sells worth $15k, the latest filed on Jan 17, 2025.
A track record needs three past buys with six months of prices behind them; John Lunger has 0, so none is measured yet.
The newest scored trade: sold $3,243 of ADAPY on Jan 17, 2025, filed Jan 17, 2025, scored 40 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ADAPY: Adaptimmune Therapeutics PLC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Adaptimmune Therapeutics PLC | $3,243 5,584 shares | -43% | - | |
| 50Moderate | Adaptimmune Therapeutics PLC | $11k 19,542 shares | -193% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 17, 2025 | ADAPY Adaptimmune Therapeutics PLC | 5,584 0.00% of outstanding | $3,243 | Jan 17, 2025 | $11k |
| Jan 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | 9,739 0.00% of outstanding | $5,726 | Jan 13, 2025 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,612,032 | $0.00 | $0 | 1,612,032 | Feb 20, 2025 |
| Feb 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,074,696 | $0.00 | $0 | 1,074,696 | Feb 20, 2025 |
| Jan 17, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,584 | $0.58 | $3,243 | 7,510 | Jan 17, 2025 |
| Jan 13, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -4,268 | $0.59 | $2,509 | 5,845 | Jan 15, 2025 |
| Jan 13, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,471 | $0.59 | $3,216 | 7,623 | Jan 15, 2025 |
| Jan 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -9,803 | $0.57 | $5,635 | 13,756 | Jan 15, 2025 |
Questions about John Lunger
Answered from the filings on this page, as of the latest one.
Is John Lunger buying or selling?
Not in the last 12 months. John Lunger's latest open-market trade on SEC Form 4 was sold $3,243 of ADAPY on Jan 17, 2025.
How did John Lunger's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Lunger has 0.
Where does John Lunger file Form 4?
John Lunger has filed Form 4 at ADAPY (Adaptimmune Therapeutics PLC) as Chief Patient Supply Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.